Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Rocbrutinib in relapsed or refractory mantle cell lymphoma is active and not recruiting. Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rocbrutinib (rocbrutinib)

Snippet

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING